Bevonium

DB13542

small molecule experimental

Deskripsi

Struktur Molekul 2D

Berat 354.469
Wujud -

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

516 Data
Aclidinium The risk or severity of adverse effects can be increased when Bevonium is combined with Aclidinium.
Mianserin Mianserin may increase the anticholinergic activities of Bevonium.
Mirabegron The risk or severity of urinary retention can be increased when Bevonium is combined with Mirabegron.
Pramlintide The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Bevonium.
Secretin porcine The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Bevonium.
Tiotropium The risk or severity of adverse effects can be increased when Bevonium is combined with Tiotropium.
Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Bevonium is combined with Topiramate.
Umeclidinium The risk or severity of adverse effects can be increased when Bevonium is combined with Umeclidinium.
Glycopyrronium The risk or severity of adverse effects can be increased when Bevonium is combined with Glycopyrronium.
Botulinum toxin type A The risk or severity of adverse effects can be increased when Bevonium is combined with Botulinum toxin type A.
Glucagon Bevonium may increase the gastrointestinal motility reducing activities of Glucagon.
Sulpiride Bevonium may increase the anticholinergic activities of Sulpiride.
Botulinum toxin type B The risk or severity of adverse effects can be increased when Bevonium is combined with Botulinum toxin type B.
Eluxadoline The risk or severity of constipation can be increased when Bevonium is combined with Eluxadoline.
Ramosetron The risk or severity of constipation can be increased when Bevonium is combined with Ramosetron.
Naltrexone The risk or severity of adverse effects can be increased when Bevonium is combined with Naltrexone.
Bezitramide The risk or severity of adverse effects can be increased when Bevonium is combined with Bezitramide.
Tramadol The risk or severity of adverse effects can be increased when Bevonium is combined with Tramadol.
Morphine The risk or severity of adverse effects can be increased when Bevonium is combined with Morphine.
Codeine The risk or severity of adverse effects can be increased when Bevonium is combined with Codeine.
Hydromorphone The risk or severity of adverse effects can be increased when Bevonium is combined with Hydromorphone.
Methadone The risk or severity of adverse effects can be increased when Bevonium is combined with Methadone.
Meperidine The risk or severity of adverse effects can be increased when Bevonium is combined with Meperidine.
Oxycodone The risk or severity of adverse effects can be increased when Bevonium is combined with Oxycodone.
Butorphanol The risk or severity of adverse effects can be increased when Bevonium is combined with Butorphanol.
Dextropropoxyphene The risk or severity of adverse effects can be increased when Bevonium is combined with Dextropropoxyphene.
Pentazocine The risk or severity of adverse effects can be increased when Bevonium is combined with Pentazocine.
Sufentanil The risk or severity of adverse effects can be increased when Bevonium is combined with Sufentanil.
Alfentanil The risk or severity of adverse effects can be increased when Bevonium is combined with Alfentanil.
Fentanyl The risk or severity of adverse effects can be increased when Bevonium is combined with Fentanyl.
Nalbuphine The risk or severity of adverse effects can be increased when Bevonium is combined with Nalbuphine.
Levorphanol The risk or severity of adverse effects can be increased when Bevonium is combined with Levorphanol.
Remifentanil The risk or severity of adverse effects can be increased when Bevonium is combined with Remifentanil.
Buprenorphine The risk or severity of adverse effects can be increased when Bevonium is combined with Buprenorphine.
Hydrocodone The risk or severity of adverse effects can be increased when Bevonium is combined with Hydrocodone.
Diphenoxylate The risk or severity of adverse effects can be increased when Bevonium is combined with Diphenoxylate.
Oxymorphone The risk or severity of adverse effects can be increased when Bevonium is combined with Oxymorphone.
Dezocine The risk or severity of adverse effects can be increased when Bevonium is combined with Dezocine.
Levacetylmethadol The risk or severity of adverse effects can be increased when Bevonium is combined with Levacetylmethadol.
Methadyl acetate The risk or severity of adverse effects can be increased when Bevonium is combined with Methadyl acetate.
Dihydroetorphine The risk or severity of adverse effects can be increased when Bevonium is combined with Dihydroetorphine.
Diamorphine The risk or severity of adverse effects can be increased when Bevonium is combined with Diamorphine.
Ethylmorphine The risk or severity of adverse effects can be increased when Bevonium is combined with Ethylmorphine.
Etorphine The risk or severity of adverse effects can be increased when Bevonium is combined with Etorphine.
Dextromoramide The risk or severity of adverse effects can be increased when Bevonium is combined with Dextromoramide.
Desomorphine The risk or severity of adverse effects can be increased when Bevonium is combined with Desomorphine.
Carfentanil The risk or severity of adverse effects can be increased when Bevonium is combined with Carfentanil.
Dihydrocodeine The risk or severity of adverse effects can be increased when Bevonium is combined with Dihydrocodeine.
Alphacetylmethadol The risk or severity of adverse effects can be increased when Bevonium is combined with Alphacetylmethadol.
Dihydromorphine The risk or severity of adverse effects can be increased when Bevonium is combined with Dihydromorphine.
Tapentadol The risk or severity of urinary retention and constipation can be increased when Bevonium is combined with Tapentadol.
Ketobemidone The risk or severity of adverse effects can be increased when Bevonium is combined with Ketobemidone.
DPDPE The risk or severity of adverse effects can be increased when Bevonium is combined with DPDPE.
Lofentanil The risk or severity of adverse effects can be increased when Bevonium is combined with Lofentanil.
Opium The risk or severity of adverse effects can be increased when Bevonium is combined with Opium.
Normethadone The risk or severity of adverse effects can be increased when Bevonium is combined with Normethadone.
Piritramide The risk or severity of adverse effects can be increased when Bevonium is combined with Piritramide.
Alphaprodine The risk or severity of adverse effects can be increased when Bevonium is combined with Alphaprodine.
Nicomorphine The risk or severity of adverse effects can be increased when Bevonium is combined with Nicomorphine.
Meptazinol The risk or severity of adverse effects can be increased when Bevonium is combined with Meptazinol.
Phenoperidine The risk or severity of adverse effects can be increased when Bevonium is combined with Phenoperidine.
Phenazocine The risk or severity of adverse effects can be increased when Bevonium is combined with Phenazocine.
Tilidine The risk or severity of adverse effects can be increased when Bevonium is combined with Tilidine.
Carfentanil, C-11 The risk or severity of adverse effects can be increased when Bevonium is combined with Carfentanil, C-11.
Benzhydrocodone The risk or severity of adverse effects can be increased when Bevonium is combined with Benzhydrocodone.
Naloxegol The risk or severity of adverse effects can be increased when Bevonium is combined with Naloxegol.
Trospium The risk or severity of adverse effects can be increased when Trospium is combined with Bevonium.
Oxyphenonium The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Bevonium.
Benzatropine The risk or severity of adverse effects can be increased when Benzatropine is combined with Bevonium.
Disopyramide The risk or severity of adverse effects can be increased when Disopyramide is combined with Bevonium.
Metixene The risk or severity of adverse effects can be increased when Metixene is combined with Bevonium.
Terfenadine The risk or severity of adverse effects can be increased when Terfenadine is combined with Bevonium.
Buclizine The risk or severity of adverse effects can be increased when Buclizine is combined with Bevonium.
Trihexyphenidyl The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Bevonium.
Oxyphencyclimine The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Bevonium.
Procyclidine The risk or severity of adverse effects can be increased when Procyclidine is combined with Bevonium.
Hyoscyamine The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Bevonium.
Methscopolamine bromide The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Bevonium.
Darifenacin The risk or severity of adverse effects can be increased when Darifenacin is combined with Bevonium.
Tridihexethyl The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Bevonium.
Anisotropine methylbromide The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Bevonium.
Atropine The risk or severity of adverse effects can be increased when Atropine is combined with Bevonium.
Nicardipine The risk or severity of adverse effects can be increased when Nicardipine is combined with Bevonium.
Mecamylamine The risk or severity of adverse effects can be increased when Mecamylamine is combined with Bevonium.
Pirenzepine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Bevonium.
Homatropine methylbromide The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Bevonium.
Benzquinamide The risk or severity of adverse effects can be increased when Benzquinamide is combined with Bevonium.
Propantheline The risk or severity of adverse effects can be increased when Propantheline is combined with Bevonium.
Dicyclomine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Bevonium.
Tropicamide The risk or severity of adverse effects can be increased when Tropicamide is combined with Bevonium.
Cocaine The risk or severity of adverse effects can be increased when Cocaine is combined with Bevonium.
Quinidine The risk or severity of adverse effects can be increased when Quinidine is combined with Bevonium.
Amantadine The risk or severity of adverse effects can be increased when Amantadine is combined with Bevonium.
Methantheline The risk or severity of adverse effects can be increased when Methantheline is combined with Bevonium.
Cycrimine The risk or severity of adverse effects can be increased when Cycrimine is combined with Bevonium.
Cyclopentolate The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Bevonium.
Tolterodine The risk or severity of adverse effects can be increased when Tolterodine is combined with Bevonium.
Oxybutynin The risk or severity of adverse effects can be increased when Oxybutynin is combined with Bevonium.
Pentolinium The risk or severity of adverse effects can be increased when Pentolinium is combined with Bevonium.
Trimethaphan The risk or severity of adverse effects can be increased when Trimethaphan is combined with Bevonium.

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul